vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Phreesia, Inc. (PHR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $120.3M, roughly 1.4× Phreesia, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 12.7%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.
ESPR vs PHR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $120.3M |
| Net Profit | — | $4.3M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 3.1% |
| Net Margin | — | 3.5% |
| Revenue YoY | 143.7% | 12.7% |
| Net Profit YoY | — | 129.7% |
| EPS (diluted) | $0.32 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $120.3M | ||
| Q3 25 | $87.3M | $117.3M | ||
| Q2 25 | $82.4M | $115.9M | ||
| Q1 25 | $65.0M | — | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | — | ||
| Q2 24 | $73.8M | — | ||
| Q1 24 | $137.7M | — |
| Q4 25 | — | $4.3M | ||
| Q3 25 | $-31.3M | $654.0K | ||
| Q2 25 | $-12.7M | $-3.9M | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | — | ||
| Q2 24 | $-61.9M | — | ||
| Q1 24 | $61.0M | — |
| Q4 25 | 50.6% | 3.1% | ||
| Q3 25 | -11.4% | -1.3% | ||
| Q2 25 | 8.6% | -2.8% | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | 3.5% | ||
| Q3 25 | -35.9% | 0.6% | ||
| Q2 25 | -15.4% | -3.4% | ||
| Q1 25 | -62.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | — | ||
| Q2 24 | -83.9% | — | ||
| Q1 24 | 44.3% | — |
| Q4 25 | $0.32 | $0.07 | ||
| Q3 25 | $-0.16 | $0.01 | ||
| Q2 25 | $-0.06 | $-0.07 | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $106.4M |
| Total DebtLower is stronger | — | $3.4M |
| Stockholders' EquityBook value | $-302.0M | $320.3M |
| Total Assets | $465.9M | $423.5M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $106.4M | ||
| Q3 25 | $92.4M | $98.3M | ||
| Q2 25 | $86.1M | $90.9M | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | — | $6.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $320.3M | ||
| Q3 25 | $-451.4M | $298.0M | ||
| Q2 25 | $-433.5M | $282.2M | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | — | ||
| Q2 24 | $-344.2M | — | ||
| Q1 24 | $-294.3M | — |
| Q4 25 | $465.9M | $423.5M | ||
| Q3 25 | $364.0M | $408.6M | ||
| Q2 25 | $347.1M | $400.4M | ||
| Q1 25 | $324.0M | — | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | — | ||
| Q2 24 | $352.3M | — | ||
| Q1 24 | $373.1M | — |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $15.5M |
| Free Cash FlowOCF − Capex | — | $12.2M |
| FCF MarginFCF / Revenue | — | 10.1% |
| Capex IntensityCapex / Revenue | 0.0% | 2.7% |
| Cash ConversionOCF / Net Profit | — | 3.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $15.5M | ||
| Q3 25 | $-4.3M | $14.8M | ||
| Q2 25 | $-31.4M | $14.8M | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | — | ||
| Q2 24 | $-7.2M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $11.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | 10.1% | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | — | 9.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | 2.7% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 3.62× | ||
| Q3 25 | — | 22.68× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PHR
| Subscription And Services | $55.5M | 46% |
| Network Solutions | $37.4M | 31% |
| Payment Processing Fees | $27.4M | 23% |
